Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

755 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Medical management of metastatic bone disease.
Vasudev NS, Brown JE. Vasudev NS, et al. Among authors: brown je. Curr Opin Support Palliat Care. 2010 Sep;4(3):189-94. doi: 10.1097/SPC.0b013e32833d3024. Curr Opin Support Palliat Care. 2010. PMID: 20671553 Review.
Sunitinib-induced severe hypothyroidism with cardiac compromise.
Collinson FJ, Vasudev NS, Berkin L, Khan MM, Selby PJ, Brown JE. Collinson FJ, et al. Among authors: brown je. Med Oncol. 2011 Dec;28 Suppl 1:S699-701. doi: 10.1007/s12032-010-9757-z. Epub 2010 Nov 30. Med Oncol. 2011. PMID: 21116874
The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic renal cancer.
Collinson FJ, Gregory WM, McCabe C, Howard H, Lowe C, Potrata D, Tubeuf S, Hanlon P, McParland L, Wah T, Selby PJ, Hewison J, Brown J, Brown J. Collinson FJ, et al. BMC Cancer. 2012 Dec 14;12:598. doi: 10.1186/1471-2407-12-598. BMC Cancer. 2012. PMID: 23241439 Free PMC article. Clinical Trial.
Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.
Powles T, Lackner MR, Oudard S, Escudier B, Ralph C, Brown JE, Hawkins RE, Castellano D, Rini BI, Staehler MD, Ravaud A, Lin W, O'Keeffe B, Wang Y, Lu S, Spoerke JM, Huw LY, Byrtek M, Zhu R, Ware JA, Motzer RJ. Powles T, et al. Among authors: brown je. J Clin Oncol. 2016 May 10;34(14):1660-8. doi: 10.1200/JCO.2015.64.8808. Epub 2016 Mar 7. J Clin Oncol. 2016. PMID: 26951309 Free PMC article. Clinical Trial.
Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy.
Hall PE, Shepherd STC, Brown J, Larkin J, Jones R, Ralph C, Hawkins R, Chowdhury S, Boleti E, Bahl A, Fife K, Webb A, Crabb SJ, Geldart T, Hill R, Dunlop J, McLaren D, Ackerman C, Wimalasingham A, Beltran L, Nathan P, Powles T. Hall PE, et al. Eur Urol Focus. 2020 Sep 15;6(5):999-1005. doi: 10.1016/j.euf.2019.01.010. Epub 2019 Feb 6. Eur Urol Focus. 2020. PMID: 30738795 Free article. Clinical Trial.
Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group.
Brown JE, Handforth C, Compston JE, Cross W, Parr N, Selby P, Wood S, Drudge-Coates L, Walsh JS, Mitchell C, Collinson FJ, Coleman RE, James N, Francis R, Reid DM, McCloskey E. Brown JE, et al. J Bone Oncol. 2020 Aug 2;25:100311. doi: 10.1016/j.jbo.2020.100311. eCollection 2020 Dec. J Bone Oncol. 2020. PMID: 32995252 Free PMC article.
755 results